James E. Bradner
Novartis (Switzerland) · 548 works · 56,345 citations · h-index 113
Top works
- Selective inhibition of BET bromodomains
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies
- PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- Transcriptional Amplification in Tumor Cells with Elevated c-Myc
- HDAC2 negatively regulates memory formation and synaptic plasticity
- Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90
- Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
- Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
- R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling
- Direct inhibition of the NOTCH transcription factor complex
- Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma
- Chemical phylogenetics of histone deacetylases
- A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia
- Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition